PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: R&D
Fixing Innovation: Lilly's CEO Says Why, and How
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, IP, Legal, Market Access, Meetings, People, R&D, Regulatory, Safety, Strategy, Technology, healthcare, leadership, pricing Also tagged CEO, CEOs, drug safety, Eli Lilly, Financial Times, Global, healthcare reform, innovation, IP, IPAB, Lilly, PhRMA, policy 1 Comment
Will WHO Member States Pony Up for Neglected Diseases?
Recognizing that traditional market forces – namely incentives related to intellectual property and a steady demand for products – have failed in developing countries, the World Health Organization (WHO) asked a member state-nominated group to come up with ways to fund R&D and pay for the treatment of neglected diseases in the world’s poorest nations. [...]
Posted in Emerging Markets, Global, IP, Legal, Manufacturing, Market Access, R&D, leadership, pricing Also tagged developing countries, developing nations, funding, neglected diseases, Neglected Tropical Diseases, Novartis, Paul Herrling, tropical diseases, WHO, World Health Assembly Leave a comment
Talkback from Tufts: Defending R&D Costs
by Joe DiMasi, director of economic analysis, Tufts Center for the Study of Drug Development
William Looney’s posting for this blog, “Calculating the Cost of R&D: Defending Tufts Research” (January 11, 2012), raises a number of interesting and important points. Both the posting and the working paper by F.M. Scherer on which the posting was based, [...]
Posted in Guest Blog, R&D, pricing Also tagged healthcare costs, Tufts Center for the Study of Drug Development 2 Comments
Witty Touts GSK Pipeline in 4th Quarter Review
brightcove.createExperiences();
Posted in Emerging Markets, Europe, Global, News, R&D, Strategy Also tagged financial, GlaxoSmithKline, GSK, patent expiries, pipeline, Research Leave a comment
Public Interest in Private Science: New Pathways to Measuring R&D Success